The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
Video navigation menu
- Effects of SGLT2 inhibitors 00:21
- SGLT2 function in the early proximale tubule 01:32
- SGLT2i and BP effects: changes in intravascular volume 05:38
- Potential mechanisms of SGLT2i 07:34
- Clinical trials with SGLT2i 10:09
What is the potential mechanism of blood pressure lowering by SGLT2i?
- A. Decrease in red cell mass
- B. Decrease in plasma volume
- C. Increase in fluid retention by the interstitial compartment
- D. Increase in skin sodium content
This lecture by Maria Rosa Costanzo was part of the EBAC-accredited symposium "Impacting cardiovascular and kidney protection in CKD: The evolving role of SGLT2i" held during the virtual ERA EDTA 2020 meeting.
Maria Rosa Costanzo, MD is a cardiologist and medical director for heart failure research at the Advocate Heart Institute in Naperville, IL, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.